Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients
Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.
How this was made

The 30-second read
Why it matters
The data show low mortality, low stroke, and strong hemodynamic performance, which could enhance the company's growth outlook.
Market read
First‑time release of positive trial data for a micro‑cap medical‑device firm, likely to move the stock.
What to watch
Regulatory approval timeline and reimbursement coverage could delay commercial impact.
Background
Anteris Technologies Global Corp. (AVR) announced one‑year clinical results for its DurAVR transcatheter heart valve in a high‑risk aortic stenosis cohort.
Ticker impact
Anteris disclosed first‑time one‑year DurAVR heart‑valve trial data showing low mortality and strong performance.
likely upward pressure as investors price in favorable clinical results
First disclosure of robust one‑year data for a high‑risk patient group; no prior public release.
Market effects
May boost confidence in transcatheter valve market and related device makers.
Limited to US and European cardiovascular device investors.
Modest; primarily affects niche medical‑device segment.
Counterpoint
Trial size is small (100 patients); long‑term durability still uncertain.
Key entities
- companyAnteris Technologies Global Corp.
Developer of the DurAVR transcatheter heart valve.
- productDurAVR Transcatheter Heart Valve
Device evaluated in the one‑year study.



